Closing of the second stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (September 27, 2018) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (“IOPtima”or the “Company”) (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), and BioLight’s announcement dated March 29, 2018 regarding completion of the first stage of the Agreement, BioLight hereby announce that the second stage was completed.

Link to the complete article

Link to Newsroom

Comments are closed.